The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
about
Advances in targeting signal transduction pathwaysNatural borneol, a monoterpenoid compound, potentiates selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake and activation of ROS-mediated DNA damageA phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathwayInvestigational agents in development for the treatment of ovarian cancerInhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat modelPhosphorylated TP63 induces transcription of RPN13, leading to NOS2 protein degradationReversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.Synergistic apoptosis-inducing effects on A375 human melanoma cells of natural borneol and curcumin.Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Red Light Combined with Blue Light Irradiation Regulates Proliferation and Apoptosis in Skin Keratinocytes in Combination with Low Concentrations of Curcumin.Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineRational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't knowMechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Inhibition of Autophagy Enhances Curcumin United light irradiation-induced Oxidative Stress and Tumor Growth Suppression in Human Melanoma CellsEnhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyQuantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.ALK-positive cancer: still a growing entity.Signaling pathways as therapeutic targets in biliary tract cancer.Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells.S-Adenosylmethionine Affects ERK1/2 and Stat3 Pathways and Induces Apotosis in Osteosarcoma Cells.miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562.Neutrophil gelatinase-associated lipocalin regulates intracellular accumulation of Rh123 in cancer cells.Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppressionBAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.MEK inhibitor enhances sensitivity to chemotherapeutic drugs in multidrug resistant hepatocellular carcinoma cells.
P2860
Q27686983-D730CC91-4955-459F-87F1-4A08FF350F5AQ28488280-3D1701F5-427E-4076-BBA5-35FFE5A46342Q30411680-505A25E7-E43C-4CEE-B624-784F3C8D0538Q33648764-C51FC9F7-B355-4CBF-9996-DC4BF65E7BB5Q33920800-3C35D03A-1D2A-4D4C-9286-EB0A85DEA4BEQ34325616-C69F5889-0DC5-471E-9490-8618F198B94DQ34438764-B9677FE3-5EFF-4719-862D-A2520FBCC631Q35114769-ECA47085-B4A3-436B-BA45-5F2796BF54CFQ35196205-C44690EB-9A42-4379-8CB0-A251D6EBF765Q35556981-72AC9CA5-89D4-443D-8BB9-67AB213A12E3Q35640301-A2FD643D-A060-4DAE-8102-9F1BC0D1F522Q35640339-201E8D99-9CB4-42BE-8393-E2BACD75990FQ35679353-21B2365F-E287-411B-A4FD-5F1C08E0A163Q35779792-E9033D33-370F-4824-B830-3EABCACA6C4EQ36059702-9E160F09-6374-4715-9F62-A82E275E49E5Q36179524-D2A5BEB0-3064-4D32-B297-2ED2A82430A6Q36304116-9EA6DCAD-DB52-472A-A50A-1CA0270E25FDQ36477469-8B8AE182-33D5-452F-8A6B-E5235C159A3EQ36556350-762D6D05-DD92-4DE1-938A-F16AFA20A1E0Q36731185-65121F65-0659-451B-A368-2683080EFDB5Q36736362-ADD2723E-923E-4E15-BF95-B453711064FAQ36862768-EF964AC4-2550-476A-B85E-9B821FB2602BQ37159980-EA38BD80-A4AC-4177-A4EA-22E0B979D8BFQ37192616-1D54E1AF-3FF9-42D9-81DD-33B5AF74E1F9Q37302721-8BC7B820-FF8C-4849-BA62-4A89544A076EQ37360181-C8F1DAD3-09DC-43B9-8C7F-C3D4782ADD6AQ37410515-80CD14F5-98C0-450A-865C-40EC835E057DQ37837732-A2033A5F-A847-49E5-8712-F608EA8A99EEQ37865381-B997F395-8BDF-45D9-AD95-D7635138F72DQ38184584-4637924E-7C74-47C9-86AE-33F6998E04D6Q38747573-B8B3BE36-486A-4047-B76F-4D30D9035A66Q38837835-52659868-9766-4BFC-B13B-DD3A225392C7Q38853093-D0063864-FCCE-4496-9319-5FEB3F514F28Q38862227-D9F5BF34-6B78-43AA-9650-8F11B7AC4D90Q39286854-E4607C19-B8A8-48EF-8074-38D67530F72BQ39300516-1623A782-DED5-4D37-9C20-AB3DC6100B33Q39411182-7522D02B-A432-405B-92CD-40A9DA883CDFQ39430569-323A9EEE-A623-4477-A22B-FCDC1B8538CCQ40862157-CA694ADE-E5BA-4248-A2A4-E1A90A5CE3B8Q41612715-47C18C0E-5F07-4957-9165-80277059B383
P2860
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Raf/MEK/ERK pathway can go ...... nsitivity to targeted therapy.
@en
The Raf/MEK/ERK pathway can go ...... nsitivity to targeted therapy.
@nl
type
label
The Raf/MEK/ERK pathway can go ...... nsitivity to targeted therapy.
@en
The Raf/MEK/ERK pathway can go ...... nsitivity to targeted therapy.
@nl
prefLabel
The Raf/MEK/ERK pathway can go ...... nsitivity to targeted therapy.
@en
The Raf/MEK/ERK pathway can go ...... nsitivity to targeted therapy.
@nl
P2093
P2860
P356
P1433
P1476
The Raf/MEK/ERK pathway can go ...... nsitivity to targeted therapy.
@en
P2093
Alberto M Martelli
Ellis W T Wong
Ferdinando Nicoletti
Franca Stivala
James A McCubrey
John G Shelton
Linda S Steelman
Massimo Libra
Stephen L Abrams
William H Chappell
P2860
P304
P356
10.4161/CC.9.9.11483
P577
2010-05-10T00:00:00Z